Stock Option Grant: On December 15, 2025, Galecto's Board approved the grant of 312,535 non-qualified stock options to a new employee at an exercise price of $32.00 per share, aimed at attracting talent and enhancing the company's competitive edge.
Incentive Plan: The grant is made under the Company's 2022 Inducement Plan, with options vesting 25% on the first anniversary and 1/48th monthly thereafter, ensuring the employee's continued employment to earn the options.
Talent Attraction: By offering attractive stock options, Galecto aims to draw key talent to support its clinical development in hematological cancer treatments, thereby strengthening its market position in the biotechnology sector.
Future Outlook: Galecto expects to submit an IND application for its lead asset DMR-001 in mid-2026, further advancing its antibody therapeutic pipeline and enhancing the company's innovative capabilities in treating blood cancers.
GLTO
$30+Infinity%1D
Analyst Views on GLTO
Wall Street analysts forecast GLTO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLTO is 32.00 USD with a low forecast of 32.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast GLTO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLTO is 32.00 USD with a low forecast of 32.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 31.600
Low
32.00
Averages
32.00
High
32.00
Current: 31.600
Low
32.00
Averages
32.00
High
32.00
Guggenheim
Buy
maintain
$32 -> $36
2025-12-08
Reason
Guggenheim
Price Target
$32 -> $36
2025-12-08
maintain
Buy
Reason
Guggenheim raised the firm's price target on Galecto (GLTO) to $36 from $32 and keeps a Buy rating on the shares. The firm considers the ASH medical meeting "a positive development" because Incyte (INCY) reported INCA033989 data that de-risk the class for myelofibrosis, but showed a probability that efficacy in Type 2 patients has "been left on the table as a competitive opening" for DMR-001, the analyst tells investors.
Guggenheim
NULL -> Buy
initiated
$32
2025-11-30
Reason
Guggenheim
Price Target
$32
2025-11-30
initiated
NULL -> Buy
Reason
Guggenheim initiated coverage of Galecto with a Buy rating and $32 price target.
About GLTO
Galecto, Inc. is a clinical-stage biotechnology company focused on the development of novel treatments for cancer and liver diseases. The Company’s pipeline consists of small molecule drug candidates that target cancer and fibrosis signaling pathways, including a preclinical dual inhibitor of ENL-YEATS and FLT3 (GB3226) for multiple genetic subsets of AML; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications and (an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis. It is developing GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 for multiple molecularly defined subsets of acute myeloid leukemia (AML). The Company’s pipeline is GB1211, its oral small molecule galectin-3 inhibitor candidate, which is in development for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
